Ascentage Pharma Announces Inclusion of Lisaftoclax in China’s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

On November 15, 2026 Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, reported that its two core assets are covered by China’s 2026 National Reimbursement Drug List (NRDL), providing more patients with greater access to innovative treatment options. Specifically:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lisaftoclax has been included in the 2026 NRDL for the first time for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
Olverembatinib has successfully renewed its NRDL coverage through renegotiation for the treatment of (1) adult patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs); and (2) adult patients with CML-CP or accelerated phase (CML-AP) harboring the T315I mutation.

With these developments, all approved indications for both of Ascentage Pharma’s novel drugs are now covered by the NRDL. The updated NRDL will officially take effect on January 1, 2027.

Lisaftoclax is a novel, oral, Bcl-2 selective inhibitor independently developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and hence restoring the normal apoptosis process in cancer cells. Approved in China in July 2025, lisaftoclax became the first domestically developed, original Bcl-2 inhibitor to receive marketing approval in the country. Its inclusion in the updated NRDL is expected to significantly improve treatment accessibility for patients with CLL/SLL in China, enabling more patients to gain timely access to new treatment options.

Olverembatinib is a novel, oral, third-generation BCR-ABL inhibitor independently developed by Ascentage Pharma, with support from China’s National Major New Drug Innovation Program. It is jointly commercialized in China by Ascentage Pharma and Innovent Biologics. Approved in China in November 2021, olverembatinib became the first third-generation BCR-ABL inhibitor to receive marketing approval in the country. The successful renewal of its NRDL coverage will continue to benefit more patients with CML in China by further improving the affordability and accessibility of long-term treatment.

Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, commented: "The successful inclusion of lisaftoclax in the NRDL and the renewal of olverembatinib’s coverage mark that all approved indications of Ascentage Pharma’s two core assets are now covered by the NRDL. For patients, it means greater access to innovative treatment options; for the company, it provides a solid basis for commercialization and sustained innovation; and for the industry, it demonstrates that China’s national reimbursement system supports domestically developed innovative drugs and further recognizes their value, boosting confidence across the pharmaceutical industry to continuously advance original innovation."

Olverembatinib and lisaftoclax are currently under investigation and have not yet been approved by the US FDA.

(Press release, Ascentage Pharma, NOV 15, 2026, View Source [SID1234674789])

Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer

On November 15, 2026 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, reported it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo (sintilimab), in combination with chemotherapy, for adults with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo would provide eligible patients across Europe with access to another first-line treatment option. The positive opinion is supported by results from the Phase 3 ORIENT-11 study (NCT03607539).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Innovent, our mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals. The positive CHMP opinion for Zybrivo marks an important regulatory milestone in our international development and brings us a step closer to serving patients in Europe." said Dr. Hui Zhou, Chief R&D Officer of Oncology at Innovent. "Zybrivo has demonstrated clear clinical benefits in the ORIENT-11 study and, if approved, could provide an additional treatment option for patients in Europe with non-squamous non-small cell lung cancer. Building on this progress, we will continue advancing our innovative pipeline and working to bring meaningful medicines to patients around the world."

Following the CHMP’s positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization will be valid across all 27 European Union (EU) member states, as well as Iceland, Norway, and Liechtenstein.

Sintilimab, as an immunotherapy, is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).

The CHMP recommendation is based on results of ORIENT-11, a randomized, multicenter, double-blind, placebo-controlled Phase 3 study that enrolled 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations, regardless of programmed death-ligand 1 (PD-L1) expression. Patients were randomized 2:1 to receive sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent radiological review committee.

In ORIENT-11, sintilimab plus chemotherapy demonstrated a 52% reduction in the hazard of disease progression or death (median PFS: 8.9 vs. 5.0 months) and a 35% reduction in the hazard of death (median overall survival (OS): 24.2 vs. 16.8 months), compared with placebo plus chemotherapy.

These results demonstrate the clinical benefit of sintilimab in combination with chemotherapy and its potential to offer an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe.

The safety profile of sintilimab in combination with chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified. Additional details may be found at clinicaltrials.gov, using identifier NCT03607539.

Zybrivo in combination with pemetrexed and platinum-based chemotherapy is indicated for the first line treatment of adult non-squamous non-small cell lung cancer (NSCLC) patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and who have:

locally advanced NSCLC and are not candidates for curative intent surgical resection or chemoradiation, or
metastatic NSCLC.
About Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death in the EU, accounting for about one in five cancer deaths.[1] An estimated 319,000 people in the EU were diagnosed with lung cancer in 2022.[2] Non-small cell lung cancer (NSCLC) is the most common form of the disease, representing 85–90% of all lung cancers.[3]

About Sintilimab
Sintilimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1), a protein that can prevent the immune system from attacking cancer cells, and blocks its interaction with the ligands PD-L1 and PD-L2[4].

Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, EGFR/ALK wild type non-squamous NSCLC, EGFR tyrosine kinase inhibitor (TKI) treatment failure non-squamous NSCLC, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin’s lymphoma. In China, sintilimab has been used to treat approximately 3 million patients[5].

Important Safety Information

Product information for sintilimab will be available from the European Medicines Agency following the European Commission decision.

This information is intended for a global audience. Product indications vary by region.

(Press release, Innovent Biologics, NOV 15, 2026, View Source [SID1234674782])

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

On November 15, 2026 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, reported development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumor suppressor function in cancer. CDKN2A-deficiency occurs in approximately 10-15% of all solid tumors, including ~70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to announce the nomination of IDE101 as our next development candidate in our precision medicine pipeline. IDE101 is a novel, first-in-class molecule that targets the key drivers of tumorigenesis resulting from CDKN2A-deficiency. We plan to focus development of IDE101 in tumors with a high frequency of CDKN2A-deficiency, including as a monotherapy agent and in combination with RAS inhibitors for pancreatic cancer and in combination with IDE892, our proprietary PRMT5 inhibitor, in MTAP-deleted solid tumors. We believe there is strong potential to drive better efficacy in these cancers by co-targeting tumor suppressor loss with IDE101 and key driver oncogene dependencies, such as KRAS, through rational combinations," said Dr. Michael White, President of Research and Development at IDEAYA Biosciences. "We are pushing ahead with urgency to complete the IND-enabling work necessary to support an IND filing in the first half of next year."

IDE101 was discovered through IDEAYA’s iterative physics-based ligand design and optimization platform and is a highly potent and selective dual CDK inhibitor with first-in-class potential and favorable drug-like properties. IND-enabling studies for IDE101 are ongoing to support an Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) in the first half of 2027, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.

(Press release, Ideaya Biosciences, NOV 15, 2026, View Source [SID1234674783])

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

On November 14, 2026 Servier reported updated four-year results from the Phase 2 FIREFLY-1 study of OJEMDA (tovorafenib) in patients aged six months to 25 years with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). The data are being presented as an oral presentation at the 31st Society for Neuro-Oncology (SNO) Annual Meeting on November 14 at 3:45 p.m. EST in Philadelphia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The four-year FIREFLY-1 analysis includes exploratory outcomes across the treatment and post-treatment observation periods, with a median study duration of 52.5 months in the registrational arm as of the June 5, 2026, data cutoff. Patients received OJEMDA orally once weekly in 28-day cycles for 26 cycles, after which they could continue treatment or enter the optional post-treatment observation period. The analysis assessed exploratory endpoints of time to next treatment and treatment-free interval to further characterize outcomes following treatment discontinuation.

"With four years of follow-up from FIREFLY-1, we are building a more complete picture of OJEMDA’s long-term outcomes, which will help physicians and families make critical treatment decisions," said Elly Barry, MD, Vice President of Clinical Development, Servier Pharmaceuticals. "We are proud to share these results, which, combined with the consistent safety profile, reinforce OJEMDA’s role as a meaningful treatment option. We remain committed to evaluating the effects of OJEMDA over time and continuing to support children, adolescents and young adults with pLGG."

Updated 4-year results from the phase 2 FIREFLY-1 study: Deep responses and prolonged time off therapy with tovorafenib in relapsed/refractory pediatric low-grade glioma – Saturday, November 14, 3:45 – 3:52 p.m. EST

Key findings from the exploratory analysis to be presented by Daniel Landi, MD, Duke University and Duke Cancer Institute, an investigator on the FIREFLY-1 trial, include:

Among the 76 efficacy-evaluable patients, median time to next treatment was 50.9 months (95% CI 36.7-not estimable [NE]).
The median time to next treatment in the three-year analysis, which was presented at SNO 2025, was 42.6 months.
Among the 41 patients who entered the optional post-treatment observation period:
76% of patients (n=31) remained treatment-free for at least 12 months, and 54% of patients (n=22) remained treatment-free for at least 24 months. The median treatment-free interval was not reached.
54% of patients (n=22) experienced tumor rebound off treatment and seven patients were retreated.
27% of patients (n=11) were retreated with OJEMDA. At last scan, nine of those patients had a smaller tumor than prior to retreatment.
Five of 13 patients with BRAF V600E mutations experienced tumor rebound and four were retreated.
The safety profile of OJEMDA remained consistent with the established profile. In the safety analysis set (n=137), the most common Grade ≥3 treatment-related adverse events (TRAEs) observed in ≥5% of patients included reduced growth velocity (36%), anemia (14%), increased CPK (11%), maculopapular rash (8%), and increased ALT (5%). There were no treatment-related deaths and no additional discontinuations due to TRAEs since the three-year data cutoff.
In the growth analysis set (n=90), 88% of patients (n=79) demonstrated growth recovery, irrespective of the degree of on-treatment growth suppression.
"For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful," said Daniel Landi, MD, Duke University and Duke Cancer Institute. "These longer-term FIREFLY-1 findings provide additional information about patient outcomes, including treatment duration and time off therapy, which may help inform discussions between physicians and families about treatment decisions."

Media Contact
Darby Malkin: [email protected]

About OJEMDA
OJEMDA (tovorafenib) is a Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Tovorafenib was granted Breakthrough Therapy and Rare Pediatric Disease designations by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration, and it was evaluated by the FDA under priority review. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma and from the European Commission for the treatment of glioma.

Please see full prescribing information including important safety information about OJEMDA at www.OJEMDA.com.

About Pediatric Low-Grade Glioma
Pediatric low-grade gliomas (pLGG) are the most common brain tumor with an estimated US incidence of 1,100 and Europe incidence of 700 children per year who are eligible for front-line systemic therapy.1,2 BRAF is the gene most commonly altered in pLGG, which includes two primary types of BRAF alterations – a BRAF gene fusion and BRAF point mutation. These BRAF alterations account for >50% of pLGG cases worldwide and prior to the introduction of OJEMDA, there were no approved treatments for people with pLGG driven by BRAF fusions.1,3

Pediatric low-grade gliomas can be chronic and relentless, with patients suffering profound side effects from both the tumor and the treatment, which may include chemotherapy and radiation. These side effects can impact their life over the long term, and may include motor deficiencies, vision loss, hormone deficiency and alterations in growth and development. Most children with pLGG will survive their cancer, but for the majority of those in whom a complete surgical resection is not possible, these tumors tend to recur frequently throughout childhood, necessitating multiple treatments. The cumulative toxicity of numerous therapies, along with the damage caused by multiple episodes of tumor progression, take a significant toll on the children and their families.

(Press release, Servier, NOV 14, 2026, View Source [SID1234674779])

CARsgen’s CAR-T Product Satri-cel Included in China’s Commercial Health Insurance Innovative Drug List

On November 14, 2026 CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, reported that satricabtagene autoleucel ("satri-cel", product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the Commercial Health Insurance Innovative Drug List (2026) (the "CHIIDL") issued by the National Healthcare Security Administration ("NHSA") and the Ministry of Human Resources and Social Security ("MOHRSS"), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. The new list was published today by the NHSA at a press conference held in Suzhou, and will officially take effect on January 1, 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CHIIDL primarily covers innovative drugs that go beyond the "basic coverage" mandate of the national basic medical insurance scheme and therefore cannot yet be included in the basic reimbursement list, but which are highly innovative, of significant clinical value, deliver substantial patient benefit, and are well suited to insurance coverage. It provides a payment basis for China’s multi-tiered healthcare security system, including commercial health insurance and mutual medical aid. Satri-cel is the first CAR T-cell therapy product for solid tumors to be included in the CHIIDL since the list was established, marking an extension of the multi-tiered healthcare security system’s support for CAR T-cell therapy from hematologic malignancies into solid tumors, which affect a considerably larger patient population.

Taking this inclusion as an opportunity, CARsgen will, on the premise of doing its utmost to ensure product quality and a stable supply, actively support the design and implementation of commercial insurance products and accelerate market access at healthcare institutions and standardized clinical use, so as to bring this first-in-class cell therapy product to more patients as soon as possible.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, "Satri-cel was approved in China this June and has been included in the national CHIIDL within the same year. This is recognition at the national level of the clinical value and the innovation of the world’s first CAR T-cell therapy for solid tumors. The CHIIDL establishes an institutionalized payment channel for high-value innovative therapies outside basic medical insurance, and brings us one step closer to truly bringing this first-in-class achievement to patients. The Company will continue to build the payment and service ecosystem together with insurers and healthcare institutions, so as to make diversified payment a workable and ever-broadening pathway."

About Satri-cel

Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.

The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).

(Press release, Carsgen Therapeutics, NOV 14, 2026, View Source [SID1234674784])